DSpace@İnönü

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ

Basit öğe kaydını göster

dc.contributor.author Esin, E
dc.contributor.author Oksuzoglu, B
dc.contributor.author Bilici, A
dc.contributor.author Cicin, I
dc.contributor.author Kostek, O
dc.contributor.author Kaplan, MA
dc.contributor.author Aksoy, S
dc.contributor.author Aktas, BY
dc.contributor.author Ozdemir, O
dc.contributor.author Alacacioglu, A
dc.contributor.author Cabuk, D
dc.contributor.author Sumbul, AT
dc.contributor.author Sakin, A
dc.contributor.author Paydas, S
dc.contributor.author Yetisir, E
dc.contributor.author Er, O
dc.contributor.author Korkmaz, T
dc.contributor.author Yildirim, N
dc.contributor.author Sakalar, T
dc.contributor.author Demir, H
dc.contributor.author Artac, M
dc.contributor.author Karaagac, M
dc.contributor.author Harputluoglu, H
dc.contributor.author Bilen, E
dc.contributor.author Erdur, E
dc.contributor.author Degirmencioglu, S
dc.contributor.author Aliyev, A
dc.contributor.author Cil, T
dc.contributor.author Olgun, P
dc.contributor.author Basaran, G
dc.contributor.author Gumusay, O
dc.contributor.author Demir, A
dc.contributor.author Tanrikulu, E
dc.contributor.author Yumuk, PF
dc.contributor.author Imamoglu, I
dc.contributor.author Oyan, B
dc.contributor.author Cetin, B
dc.contributor.author Haksoyler, V
dc.contributor.author Karadurmus, N
dc.contributor.author Erturk, I
dc.contributor.author Evrensel, T
dc.contributor.author Yilmaz, H
dc.contributor.author Beypinar, I
dc.contributor.author Kocer, M
dc.contributor.author Pilanci, KN
dc.contributor.author Seker, M
dc.contributor.author Urun, Y
dc.contributor.author Eren, T
dc.contributor.author Demirci, U
dc.date.accessioned 2022-10-11T13:33:24Z
dc.date.available 2022-10-11T13:33:24Z
dc.date.issued 2019
dc.identifier.uri http://hdl.handle.net/11616/76400
dc.description.abstract PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
dc.source CANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.title Pertuzumab, trastuzumab and taxane-based treatment for visceral organ
dc.title metastatic, trastuzumab-naive breast cancer: real-life practice outcomes


Bu öğenin dosyaları:

Dosyalar Boyut Biçim Göster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster